What happens when you get a bunch of experts in a room and ask them all sorts of questions, like: when will I be able to watch shows over the Internet? You realize how complex things are, how little you know, and how foggy the future is to the experts. ...

SAN JOSE, November 9th, 2006 (PodTech News)–Modern consumers are not only tech savvy, they’re also thirsty to be tuned in, unplugged, and turned on at all times and instantly with innovative digital products. This past week Dow Jones brought together the most promising consumer-oriented startups along with industry-leading executives and ...

The Web 2.0 mantra is that old media — NBC, Hearst, Disney, etc. — are too incompetent to be successful on the Web. The reality is that old media has invested a lot of time, effort and money in positioning their valuable offline properties to make money online. Some of ...

SAN JOSE, November 8, 2006 (PodTech News)–Sony launches the PlayStation 3 later this month — its most important product launch in years. Featuring Blu-ray technology and other features, the new device has a lot is riding on it. Sony Computer Entertainment America President and CEO Kaz Hirai is on ...

Understanding what consumers are doing with new media is instrumental. Speaking together at the Dow Jones VentureWire Consumer Technology Ventures Conference, Larry Gerbrandt tells PodTech’s Jennifer Jones about iPod research that will move the needle for executives assessing podcasts.

Click here for transcript.

Yahoo is making headway by being bold and thinking young. Jennifer Jones of PodTech interviews Marco Boerries at the Dow Jones Venture Wire Consumer Technology Ventures Conference about Yahoo’s strategies for connecting users whether they are on the road, at home or at work.

Tengion is a leader in the field of regenerative medicine, developing new human tissues and organs derived from a patient’s own cells. Tengion’s patented technology has the potential to allow adults and children with organ failure to have functioning organs built from their own tissues. At the Dow Jones ...

Despite President Bush’s veto of the embryonic stem cell bill almost two months ago, many venture capitalists consider the stem cell market to be viable… though just not yet for some investors. When and why will a venture capitalist invest in a stem cell company? How does the venture industry ...

Venture capitalist Andy Kessler says silicon is going to do to the health care industry what it has done to portable devices and the Internet. Where will it start? With diagnostics, according to Kessler, who delivered the lunch keynote at the Dow Jones VentureWire Health Care Innovations conference in ...

Getting money for a Series B round in health care deals results in a “down round” at least 50 percent of the time. Ralph (Chris) Christoffersen, a general partner at Morgenthaler Ventures, tells PodTech’s Jennifer Jones how his firm helps CEOs manage through the process of getting financed in the ...

Patients desire improved treatments, voters call for safety, biomed startups want drug approval to continue in business and big pharma is after big profits. The Food and Drug Administration must grapple with these issues, which are only getting more complex. Dr. Steve Galson, director of the FDA’s Center for ...

The U.S. Food and Drug Administration says it is a constant balancing act to determine how much risk to consumers is acceptable in the drug approval process. No risk would result in few drugs coming to market. Some risk allows more. But Dr. Steve Galson, director of the FDA’s ...